InSightec Panel Acquiesces Despite Efficacy, Control Group Concerns
This article was originally published in The Gray Sheet
Executive Summary
Labeling for InSightec's ExAblate 2000 non-invasive uterine fibroid treatment should describe "mitigations" to minimize the risk of nerve damage during the procedure, FDA advisory panel members recommend